Pressure BioSciences to Expand on Pivotal Change in Business Strategy with Presentation at H. C. Wainwright Annual Global Investment Conference on September 13th

Enterprise Shifts Primary Company Concentrate to Revolutionary UST Platform. Expects to Enter FY 2023 with

Ten or A lot more Tolling Contracts. Thinks Each Agreement Could Generate $1 Million or More in PBI Earnings.

SOUTH EATON, MA / ACCESSWIRE / September 13, 2022 / Tension BioSciences, Inc. (OTCQB:PBIO) (“PBI” and the “Corporation”), a leader in the advancement and sale of impressive, broadly enabling, strain-dependent devices, consumables, and specialty testing products and services to the worldwide daily life sciences, nutraceuticals, cosmetics, meals & beverage, and other important industries, now declared the Company’s participation in the September 12-14 H. C. Wainwright Yearly International Trader Conference. This conference will characteristic a variety of thrilling, promptly-growing community and non-public businesses, presenting for 30 minutes every single. PBI’s President and CEO, Mr. Richard T. Schumacher, will be talking on September 13th at 1:30 pm ET.

About the earlier four months, PBI has announced the execution of a few agreements covering the production, distribution, professional roll-out, and money partnership for novel, correctly h2o-soluble, remarkably bioavailable, nanoemulsified CBD products for both of those oral and topical use. Recently, the Enterprise also declared the execution of a cosmeceuticals partnership with Dr. Denese SkinScience, a 20-calendar year skincare field chief with more than $500 million in QVC sales.

All four contracts are based on the use of the Firm’s patented, Ultra Shear Technology™ (UST™) system to develop nanoemulsions of oil-based nutraceuticals and cosmetics. Nanoemulsions are recognised to flip oil-dependent active component mixtures (e.g., CBD, THC, Astaxanthin, Curcumin, Retinol, Prednisone) into very long-phrase secure, successfully h2o-soluble, hugely bioavailable formulations. The Company believes these 4 contracts by yourself could make more than $5 million of accretive profits for PBI in 2023. The Corporation programs to near on a least of six additional contracts more than the remaining months of FY 2022.

Day: Tuesday, September 13, 2022 (1:30 pm ET)

PRESENTATION: Movie Webcast – Presentation as well as Q&A

Register: Website link to PBIO Presentation – HCW Trader Conf.

Highlights of PBI’s Recent Press Releases on the Launch of UST-Processed, Nanoemulsified CBD and Cosmeceutical Merchandise – with Approximated Annual 2023 Income to PBI Anticipated to Exceed $5,000,000:

  • PBI has executed 3 contracts that contact for the Company to manufacture thousands of liters of UST-processed CBD nanoemulsion bulk product for the duration of Q4 2022
  • CBD bulk nanoemulsion product will be sent to the Firm’s contractors who will vial, label, sell, and distribute the content by using their e-commerce web pages, sub-distributors, and other recognized sales channels
  • These unique solutions are anticipated to be prolonged-term secure, effectively water-soluble, extremely bioavailable nanoemulsions of CBD for oral and topical use
  • Formulation of the preliminary items has been done: only plant-dependent reagents are utilized in the products
  • Safer Medical of Montana (SMM), Cover CBD Farms (CCF), and North Star Holdings (NSH) will associate with PBI on output, distribution, commercial roll-out, and financial returns – terms of these partnerships are in agreements that have been not too long ago executed by the businesses and PBI
  • These companies have distribution channels and infrastructure for their recent well being & wellness products
  • PBI thinks very first-yr product sales (FY 2023) will satisfy or exceed $5M in income for PBI
  • PBI thinks no other CBD merchandise on the sector can contend with the high-quality of its UST-processed Nano-CBD
  • PBI has also announced a partnership with Dr. Denese SkinScience to manufacture new and to greatly enhance present skincare products marketed underneath the Dr. Denese label. UST-processed solutions are expected for FY 2023 launch.

About H.C. Wainwright

H.C. Wainwright is a full‐service financial investment lender devoted to furnishing company finance, strategic advisory, corporate access, and relevant expert services to general public and private providers throughout numerous sectors and regions. H.C. Wainwright & Co. also provides fairness analysis and gross sales & investing services to institutional traders. In accordance to Placement Tracker, H.C. Wainwright’s workforce is rated as the #1 Placement Agent in terms of combination CMPO (confidentially promoted general public giving), RD (registered direct providing) and PIPE (personal investment decision in general public equity) executed cumulatively given that 1998. For much more info pay a visit to H.C. Wainwright & Co. on the Online at www.hcwco.com

About Stress BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a chief in the improvement and sale of innovative, broadly enabling, stress-based methods for the throughout the world lifestyle sciences and other industries. Our products and solutions are centered on the exclusive attributes of the two consistent (i.e., static) and alternating (i.e., strain cycling technological innovation, or PCT) hydrostatic strain. PCT is a patented enabling engineering system that utilizes alternating cycles of hydrostatic stress in between ambient and ultra-high ranges to manage bio-molecular interactions properly and reproducibly (e.g., mobile lysis, biomolecule extraction). Our main focus is the growth of PCT-dependent products for biomarker and target discovery, drug design and progress, biotherapeutics characterization and excellent command, soil & plant biology, forensics, and counter-bioterror purposes. On top of that, significant new current market prospects have emerged in the use of our stress-centered systems in the next areas: (1) the use of our not long ago acquired, patented technological innovation from BaroFold, Inc. (the “BaroFold” technological know-how) to make it possible for entry into the bio-pharma contract products and services sector, and (2) the use of our a short while ago-patented, scalable, substantial-performance, strain-based mostly Extremely Shear Technology (“UST”) system to (i) generate secure nanoemulsions of normally immiscible fluids (e.g. oils and water) and to (ii) prepare increased quality, homogenized, extended shelf-lifetime or room temperature stable low-acid liquid foods that can not be successfully preserved working with current non-thermal systems.

Ahead Searching Statements

This push release has ahead-on the lookout statements. These statements relate to long run functions or our long term financial performance and involve recognised and unknown risks, uncertainties and other factors that could bring about our or our industry’s genuine effects, ranges of exercise, overall performance, or achievements to be materially unique from any long run success, stages of activity, performance or achievements expressed, implied, or inferred by these ahead-hunting statements. In some circumstances, you can identify forward-on the lookout statements by terminology these as “might,” “will,” “must,” “could,” “would,” “expects,” “designs,” “intends,” “anticipates,” “thinks,” estimates,” “predicts,” “projects,” “possible” or “go on” or the unfavorable of such conditions and other comparable terminology. These statements are only predictions primarily based on our existing expectations and projections about long run gatherings. You need to not spot undue reliance on these statements. In assessing these statements, you need to exclusively look at many components. Precise functions or benefits may differ materially. These and other elements may possibly result in our precise results to vary materially from any forward-wanting assertion. These hazards, uncertainties, and other aspects incorporate, but are not limited to, the dangers and uncertainties reviewed underneath the heading “Hazard Elements” in the Firm’s Yearly Report on Kind 10-K for the calendar year ended December 31, 2021, and other experiences filed by the Business from time to time with the SEC. The Company undertakes no obligation to update any of the information incorporated in this release, other than as usually needed by legislation.

For a lot more information and facts about PBI and this push launch, make sure you click on the following web site backlink:

http://www.pressurebiosciences.com

You should check out us on Fb, LinkedIn, and Twitter.

Supply: Tension BioSciences Inc.